Table 1. Baseline characteristics for controls and patients with CKD and ESRD.
Control (N = 11024) |
CKD (N = 5512) |
ESRD (N = 1378) |
P value | ||||
---|---|---|---|---|---|---|---|
Age, years | n | (%) | n | (%) | n | (%) | 1.0000 |
20–29 | 368 | (3.3) | 184 | (3.3) | 46 | (3.3) | |
30–39 | 848 | (7.7) | 424 | (7.7) | 106 | (7.7) | |
40–49 | 2232 | (20.3) | 1116 | (20.3) | 279 | (20.3) | |
50–59 | 2280 | (20.7) | 1140 | (20.7) | 285 | (20.7) | |
60–69 | 2504 | (22.7) | 1252 | (22.7) | 313 | (22.7) | |
≥70 | 2792 | (25.3) | 1396 | (25.3) | 349 | (25.3) | |
Sex | 1.0000 | ||||||
Female | 5768 | (52.3) | 2884 | (52.3) | 721 | (52.3) | |
Male | 5256 | (47.7) | 2628 | (47.7) | 657 | (47.7) | |
Low income | 298 | (2.7) | 232 | (4.2) | 109 | (7.9) | <0.0001 |
Medical conditions | |||||||
Hypertension | 3895 | (35.3) | 2798 | (50.8) | 912 | (66.2) | <0.0001 |
Anemia | 1204 | (10.9) | 1309 | (23.8) | 880 | (63.9) | <0.0001 |
Ischemic heart disease | 1945 | (17.6) | 1864 | (33.8) | 600 | (43.5) | <0.0001 |
Diabetes | 1600 | (14.5) | 1522 | (27.6) | 571 | (41.4) | <0.0001 |
Mental disorders | 3258 | (29.6) | 2453 | (44.5) | 473 | (34.3) | <0.0001 |
COPD | 2482 | (22.5) | 2001 | (36.3) | 333 | (24.2) | <0.0001 |
Heart failure | 406 | (3.7) | 585 | (10.6) | 288 | (20.9) | <0.0001 |
Traumatic brain injury | 1035 | (9.4) | 729 | (13.2) | 169 | (12.3) | <0.0001 |
Hyperlipidemia | 1278 | (11.6) | 1072 | (19.5) | 162 | (11.8) | <0.0001 |
Liver cirrhosis | 517 | (4.7) | 514 | (9.3) | 139 | (10.1) | <0.0001 |
Atrial fibrillation | 306 | (2.8) | 291 | (5.3) | 94 | (6.8) | <0.0001 |
Peripheral vascular disease | 210 | (1.9) | 204 | (3.7) | 65 | (4.7) | <0.0001 |
Epilepsy | 92 | (0.8) | 84 | (1.5) | 34 | (2.5) | <0.0001 |
Type of medication | |||||||
Anticoagulant | 688 | (6.2) | 706 | (12.8) | 712 | (51.7) | <0.0001 |
Anti-hypertension | 2944 | (26.7) | 2204 | (40.0) | 667 | (48.4) | <0.0001 |
Statin | 2046 | (18.6) | 1668 | (30.3) | 465 | (33.7) | <0.0001 |
COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease.